CEST theranostics: Label-free MR imaging of anticancer drugs

49Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

Abstract

Image-guided drug delivery is of great clinical interest. Here, we explored a direct way, namely CEST theranostics, to detect diamagnetic anticancer drugs simply through their inherent Chemical Exchange Saturation Transfer (CEST) MRI signal, and demonstrated its application in image-guided drug delivery of nanoparticulate chemotherapeutics. We first screened 22 chemotherapeutic agents and characterized the CEST properties of representative agents and natural analogs in three major categories, i.e., pyrimidine analogs, purine analogs, and antifolates, with respect to chemical structures. Utilizing the inherent CEST MRI signal of gemcitabine, a widely used anticancer drug, the tumor uptake of the i.v.-injected, drug-loaded liposomes was successfully detected in CT26 mouse tumors. Such label-free CEST MRI theranostics provides a new imaging means, potentially with an immediate clinical impact, to monitor the drug delivery in cancer.

Cite

CITATION STYLE

APA

Li, Y., Chen, H., Xu, J., Yadav, N. N., Chan, K. W. Y., Luo, L., … Liu, G. (2016). CEST theranostics: Label-free MR imaging of anticancer drugs. Oncotarget, 7(6), 6369–6378. https://doi.org/10.18632/oncotarget.7141

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free